Schrödinger, Inc. , 120 West 45th Street, New York, New York 10036, United States.
J Am Chem Soc. 2015 Feb 25;137(7):2695-703. doi: 10.1021/ja512751q. Epub 2015 Feb 12.
Designing tight-binding ligands is a primary objective of small-molecule drug discovery. Over the past few decades, free-energy calculations have benefited from improved force fields and sampling algorithms, as well as the advent of low-cost parallel computing. However, it has proven to be challenging to reliably achieve the level of accuracy that would be needed to guide lead optimization (∼5× in binding affinity) for a wide range of ligands and protein targets. Not surprisingly, widespread commercial application of free-energy simulations has been limited due to the lack of large-scale validation coupled with the technical challenges traditionally associated with running these types of calculations. Here, we report an approach that achieves an unprecedented level of accuracy across a broad range of target classes and ligands, with retrospective results encompassing 200 ligands and a wide variety of chemical perturbations, many of which involve significant changes in ligand chemical structures. In addition, we have applied the method in prospective drug discovery projects and found a significant improvement in the quality of the compounds synthesized that have been predicted to be potent. Compounds predicted to be potent by this approach have a substantial reduction in false positives relative to compounds synthesized on the basis of other computational or medicinal chemistry approaches. Furthermore, the results are consistent with those obtained from our retrospective studies, demonstrating the robustness and broad range of applicability of this approach, which can be used to drive decisions in lead optimization.
设计紧密结合的配体是小分子药物发现的主要目标。在过去的几十年中,自由能计算得益于改进的力场和采样算法,以及低成本并行计算的出现而受益。然而,事实证明,要可靠地实现指导先导优化(结合亲和力提高约 5 倍)所需的精度水平具有挑战性,对于广泛的配体和蛋白质靶标而言都是如此。毫不奇怪,由于缺乏大规模验证以及与运行此类计算相关的传统技术挑战,自由能模拟的广泛商业应用受到限制。在这里,我们报告了一种方法,该方法在广泛的目标类别和配体中实现了前所未有的精度水平,回顾性结果涵盖了 200 种配体和各种化学修饰,其中许多涉及配体化学结构的重大变化。此外,我们已经将该方法应用于前瞻性药物发现项目,并发现所预测的具有高活性的化合物的质量有了显著提高。与基于其他计算或药物化学方法合成的化合物相比,该方法预测具有高活性的化合物的假阳性率大大降低。与基于其他计算或药物化学方法合成的化合物相比,该方法预测具有高活性的化合物的假阳性率大大降低。与基于其他计算或药物化学方法合成的化合物相比,该方法预测具有高活性的化合物的假阳性率大大降低。该方法预测具有高活性的化合物的假阳性率大大降低。此外,结果与我们的回顾性研究结果一致,证明了该方法的稳健性和广泛的适用性,可用于指导先导优化决策。